Lesson 6 of 11 · 18 min
Active and passive immunity, antibody data and vaccines
Compare active and passive immunity, naturally and artificially acquired, interpret primary and secondary antibody responses, and explain how vaccines are developed and tested.
What you will be able to do
- Compare active and passive immunity, and naturally and artificially acquired immunity, with an example of each.
- Interpret long-term immune response data, comparing the lag, peak and duration of primary and secondary responses.
- Describe the main types of vaccine and the stages of vaccine development.
- Describe how Rosalyn Yalow's radioimmunoassay made it possible to measure tiny amounts of antigens and hormones.
A newborn baby has met almost no pathogens, yet for its first few months it rarely catches the measles its mother had as a child. A bushwalker bitten by an eastern brown snake is given antivenom and survives. Both are protected by antibodies they did not make themselves. The difference between making your own antibodies and receiving someone else's is the difference between active and passive immunity.
Definition
Active and passive
- Active immunity: your own immune system responds to an antigen, making antibodies and memory cells. It takes one to two weeks to develop but lasts years, often for life.
- Passive immunity: you receive antibodies made by another organism. It works at once but makes no memory cells, so it fades as the antibodies are broken down, over weeks to months.
Each can be naturally acquired (in normal life) or artificially acquired (by medical intervention).
| Immunity | Naturally acquired | Artificially acquired |
|---|---|---|
| Active | Infection: recovering from chickenpox leaves memory cells against the varicella virus. | Vaccination: the MMR vaccine makes your body produce antibodies and memory cells against measles, mumps and rubella. |
| Passive | Antibodies from the mother cross the placenta before birth, and are in breast milk (especially colostrum) after it. | An injection of antibodies: snake antivenom, tetanus immunoglobulin, or an antibody given to infants against respiratory syncytial virus (RSV). |
Choose each card, then the box it belongs in. For every one, ask who made the antibodies, and whether it happened in ordinary life or by a medical intervention.
A person bitten by a bat is given an injection of rabies immunoglobulin (antibodies against rabies virus) on the same day, and a course of rabies vaccine over the next two weeks. Which types of immunity do the two treatments give?
Active immunity works because of memory cells. The graph shows what happens to the concentration of one antibody in the blood when a person meets an antigen for the first time, and again five weeks later.
A typical primary and secondary antibody response to the same antigen (arbitrary units). The first exposure is on day 0.
| Feature | Primary response | Secondary response |
|---|---|---|
| Lag before antibody rises | About 5 days: only a few matching lymphocytes exist, and they must be selected, activated and cloned | Under a day or two: many memory cells respond at once |
| Peak concentration | 10 units, at about day 12 | About 100 units, at about day 40 (5 days after exposure): ten times higher |
| Duration | Falls back close to zero within weeks | Stays high for much longer |
| Outcome | You are often ill while it builds up | The pathogen is usually destroyed before symptoms appear |
From the graph, how many times higher is the peak antibody concentration of the secondary response than that of the primary response?
Worked example
Compare primary and secondary antibody responses from data
A volunteer's antibody concentration (arbitrary units) was measured after a first dose of a vaccine and again after a second dose of the same vaccine six months later.
| Days after dose | 0 | 3 | 6 | 9 | 12 | 15 | 18 | 21 |
|---|---|---|---|---|---|---|---|---|
| First dose | 0 | 0 | 2 | 8 | 12 | 9 | 5 | 3 |
| Second dose | 0 | 40 | 110 | 130 | 120 | 100 | 85 | 70 |
(a) Compare the lag phase of the two responses. (b) Calculate how many times greater the peak of the second response is. (c) Explain the differences.
Step 1: Lag
After the first dose no antibody was detected until day 6, so the lag was between 3 and 6 days. After the second dose antibody was already at 40 units by day 3, so the lag was less than 3 days.
Read where each row first rises above zero, and give the interval if the exact day is between readings.
Step 2: Peaks
First peak: units at day 12. Second peak: units at day 9.
Step 3: Ratio
, so the second peak is about times greater.
Step 4: Explain
The first dose caused a primary response: only a few B cells matched the antigen, and they had to be selected, activated and cloned before plasma cells made antibody. It also left memory B cells, many more than the original matching cells. At the second dose these responded at once and divided rapidly into plasma cells, giving a secondary response with a shorter lag, a higher peak (reached sooner) and antibody levels that stayed higher for longer.
Try it yourself first, then check the working one step at a time.
Answer
(a) Lag of 3–6 days after the first dose but under 3 days after the second. (b) About 11 times (130 ÷ 12 = 10.8). (c) Memory B cells from the first dose responded rapidly to the second.
Method
Quote values with units and days from the data.
"How many times" is a ratio: divide.
Explain with memory cells: more of them, already selected, so faster and larger.
Watch out for
Subtracting the peaks (118) when the question asks how many times greater.
Saying the second dose "has more antibodies in it". The vaccine contains antigen, not antibody.
Move the cursor along the graph. When does the antibody level first pass the protective level after each exposure? Then try the passive scenario: what happens to injected antibodies over time?
Key idea
Why boosters work
A vaccine gives a primary response, and its memory cells make any later meeting with the real pathogen a secondary response. Some vaccines need booster doses: each further dose is a secondary response that lifts antibody levels higher and builds more memory cells. The Australian Immunisation Handbook recommends a tetanus booster for adults at age 50, and another after a tetanus-prone wound if the last dose was more than five years earlier. Influenza vaccine is given every year for a different reason: the virus's surface antigens keep changing, so last year's memory cells may not recognise this year's strain.
| Type | What it contains | Examples |
|---|---|---|
| Live attenuated | A weakened pathogen that can still reproduce a little; strong, long-lasting immunity, but not for people with weak immune systems | MMR, chickenpox (varicella), oral rotavirus |
| Inactivated | Whole pathogen killed by heat or chemicals | Injected polio (Salk), hepatitis A, most influenza vaccines |
| Subunit or recombinant | Only selected antigens, often made by genetically modified cells; some form virus-like particles | Hepatitis B, human papillomavirus (HPV), whooping cough (acellular) |
| Toxoid | An inactivated exotoxin | Tetanus, diphtheria |
| mRNA | mRNA, in lipid nanoparticles, coding for one antigen; your cells make the antigen briefly | COVID-19 vaccines (Pfizer-BioNTech, Moderna) |
| Viral vector | A harmless virus engineered to carry the gene for one antigen | Some COVID-19 and Ebola vaccines |
How a vaccine is developed and tested
Research and design
Identify an antigen that produces protective immunity and choose a vaccine type.
Preclinical testing
Test in cell cultures and in animals for an immune response and safety.
Phase I
A small group of healthy adult volunteers (tens): is it safe, and does it produce an immune response?
Phase II
Hundreds of people, including the groups it is meant for: the best dose and schedule, and more safety data.
Phase III
Thousands of people in a randomised, controlled, usually double-blind trial against a placebo: does it actually prevent the disease (efficacy), and are rarer side effects found?
Approval and monitoring
A regulator (in Australia, the Therapeutic Goods Administration) reviews the evidence. After approval, surveillance (phase IV) watches for very rare side effects in millions of people.
History
A vaccine from Queensland
In 1991 Ian Frazer and Jian Zhou at the University of Queensland found a way to make the outer protein of human papillomavirus assemble into empty virus-like particles: they look like the virus to the immune system but contain no DNA, so they cannot cause infection. That discovery became the HPV vaccine, approved in Australia and the United States in 2006. HPV causes almost all cervical cancers. Australia was one of the first countries to fund HPV vaccination for schoolgirls through its National Immunisation Program (from 2007; boys were added in 2013), and it is on track to eliminate cervical cancer as a public health problem by 2035.
History
Rosalyn Yalow and the radioimmunoassay
In the 1950s, at the Veterans Administration Hospital in the Bronx, New York, the physicist Rosalyn Sussman Yalow and the physician Solomon Berson were tracing insulin labelled with radioactive iodine to see how quickly the body removes it. In people who had been injected with insulin for months or years, the labelled insulin stayed in the blood longer, because it was bound to antibodies the patients had made against the injected (animal) insulin. Science and the Journal of Clinical Investigation both rejected their paper at first, because most scientists did not believe the immune system would respond to such a small molecule. The Journal of Clinical Investigation published it in 1956 only after they took the word "antibody" out of the title.
Turning the problem around, they used those antibodies to measure insulin. In a radioimmunoassay (RIA), a known amount of radioactive antigen and the unknown amount of unlabelled antigen in a blood sample compete for a limited number of antibody binding sites. The more antigen in the sample, the less radioactivity ends up bound to the antibody. RIA could detect a billionth of a gram of a hormone or less, and it was soon used to measure hormones, drugs and viral antigens, including screening donated blood for hepatitis B virus. Yalow and Berson chose not to patent it. Berson died in 1972, and in 1977 Yalow shared the Nobel Prize in Physiology or Medicine "for the development of radioimmunoassays of peptide hormones", the second woman to win it. Modern tests such as ELISA and rapid antigen tests use the same principle: antibodies that bind one antigen, with a signal you can measure.
In a radioimmunoassay, a blood sample from patient X gives less radioactivity bound to the antibody than a sample from patient Y. What can you conclude?
Summary
Active immunity: your own antibodies and memory cells, from infection (natural) or vaccination (artificial); slow to start, long-lasting.
Passive immunity: someone else's antibodies, across the placenta or in breast milk (natural) or by injection (artificial); immediate but short-lived.
A secondary response has a shorter lag, a much higher peak and lasts longer than a primary response, because of memory cells.
Vaccines contain live attenuated or inactivated pathogens, subunits, toxoids, or mRNA or vectors coding for an antigen; they pass preclinical tests and phase I–III trials before approval.
Yalow and Berson's radioimmunoassay used competition for antibodies to measure tiny amounts of antigen; Yalow shared the 1977 Nobel Prize.
Finished the lesson?
Try the 3 quick checks above and the lesson completes itself, or mark it complete now.